Skip to main content
. 2005 May 18;7(Suppl 3):S19–S25. doi: 10.1186/ar1739

Table 3.

Reasons why oncology experience with rituximab is most helpful

Non-Hodgkin's lymphoma and autoimmune diseases have similarities
Provides information on chronic use
Provides a large safety database of >370,000 patient exposures
Provides 7 years of postmarketing experience
Extensive experience allows us to predict and manage infusion reactions
Low infection rate in oncology provides information on potential for infection in rheumatoid arthritis